0
Menu
Upload Prescription

Duo 5

Thumbnail
Duo 5
Antibiotic

1 Strip = 4 Tablets

Incepta Pharmaceuticals Ltd.
Generic Name: Cefpodoxime Proxetil + Clavulanic Acid
MRP ৳ 200 13% Off
Best Price ৳ 175
Order Now
Product Description

The combination of Cefpodoxime Proxetil and Clavulanic Acid is an advanced oral therapeutic pairing designed to overcome bacterial resistance in moderate-to-severe respiratory, urinary, and skin infections. Cefpodoxime Proxetil is a third-generation cephalosporin prodrug that, upon absorption, is de-esterified into its active form, cefpodoxime; it exerts bactericidal activity by binding to penicillin-binding proteins (PBPs), thereby disrupting the final stages of peptidoglycan cross-linking and causing cell wall synthesis failure. While cefpodoxime offers an expanded spectrum of activity against Gram-negative organisms compared to earlier generations, it remains vulnerable to hydrolysis by beta-lactamase enzymes produced by resistant bacteria. To neutralize this threat, Clavulanic Acid is added as a "suicide inhibitor"; it binds irreversibly to the active site of these enzymes, preventing them from degrading the cefpodoxime molecule and thus restoring its efficacy against beta-lactamase-producing strains like Haemophilus influenzae and Moraxella catarrhalis. Pharmacokinetically, this combination is highly effective due to its enhanced stability and broad tissue distribution, reaching therapeutic concentrations in the lungs, middle ear fluid, and sinus mucosa. Clinical use is particularly indicated for community-acquired pneumonia, acute otitis media, and chronic bronchitis exacerbations where resistance is suspected. The most common adverse effects are gastrointestinal, including diarrhea—often exacerbated by the clavulanic acid component—nausea, and abdominal pain. Patients should be screened for a history of Type I hypersensitivity reactions to penicillins or cephalosporins due to the risk of anaphylaxis. Additionally, because cefpodoxime absorption is pH-dependent, the concurrent use of antacids or H2-receptor antagonists can significantly reduce its bioavailability, potentially leading to sub-therapeutic levels and treatment failure.

Cart

Your cart is empty